Bristol-Myers Squibb Company logo
Bristol-Myers Squibb Company (BMY)
Compare

Bristol-Myers Squibb Company (BMY) Stock Price: $56.48+0.91 (+1.64%)

The total return cagr for Bristol-Myers Squibb Company (BMY) stock is 21.06% over the past 12 months. The 3 year average growth rate is 0.06% and the 5 year cagr is 1.10%. Total return includes dividends reinvested.

The closing share price for Bristol-Myers Squibb Company (BMY) stock was $56.48 for Tuesday, June 9, 2026, up +1.64% from the previous day.

BMY Price Chart

End-of-day pricesAdvanced chart →
BMY$56.48 19.59%as of Jun 9, 2026

BMY Earnings Preview

Next Earnings Date

Jul 30, 2026

51 days away

EPS Estimate

1.61

Revenue Est.

$11.70B

Last Quarter Results

EPS

$1.58

vs Estimate

$1.42

Beat

Revenue

$11.49B

vs Estimate

$10.93B

Beat

BMY Analyst Ratings

Consensus Rating

Hold

Based on 25 analysts

Strong Buy
4
Buy
6
Hold
18
Sell
1
Strong Sell
0

Average Price Target

$63.08

+11.7% upside

Low

$40.00

Current

$56.48

High

$75.00

BMY Analyst Estimates

Forward P/E: 9.20

Earnings Per Share (EPS) Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2027N/A$1.38N/A6
Q2 2027N/A$1.55N/A6
Q3 2027N/A$1.53N/A6
Q4 2027N/A$1.55N/A6

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$6.14N/A17
FY 2028N/A$5.39N/A9

Revenue Estimates

Quarterly

PeriodLowAvgHigh# Analysts
Q1 2027N/A$10.91BN/A6
Q2 2027N/A$11.43BN/A6
Q3 2027N/A$11.60BN/A6
Q4 2027N/A$12.05BN/A6

Annual

PeriodLowAvgHigh# Analysts
FY 2027N/A$46.30BN/A17
FY 2028N/A$40.98BN/A9

Source: FMP Analyst Consensus Estimates. Forward P/E calculated using average EPS estimate for the nearest fiscal year.

BMY Competitors' Key Metrics

StockMarket CapClose PricePrice ChangeTTM Total Return5Y CAGR10Y CAGR
1BMY$115.34B$56.48+1.64%+21.06%+1.10%+0.95%

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

Princeton, NJ
34,100 employees
Healthcare / Drug Manufacturers - General
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Christopher S. Boerner